×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LUMO – lumos pharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LUMO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
09:10 am
lumo
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of Action [Yahoo! Finance]
Low
Report
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201's Unique Pulsatile Mechanism of Action [Yahoo! Finance]
11/21
09:00 am
lumo
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
Low
Report
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
11/8
11:37 am
lumo
Lumos Pharma, Inc. (NASDAQ: LUMO) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.25 price target on the stock.
Low
Report
Lumos Pharma, Inc. (NASDAQ: LUMO) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.25 price target on the stock.
11/6
02:38 pm
lumo
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
Low
Report
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
10/30
04:05 pm
lumo
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62n? Annual ESPE Meeting 2024
Low
Report
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62n? Annual ESPE Meeting 2024
10/24
07:50 pm
lumo
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ZUO, ARC on Behalf of Shareholders
Neutral
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ZUO, ARC on Behalf of Shareholders
10/24
03:27 pm
lumo
Lumos Pharma, Inc. (NASDAQ: LUMO) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.25 price target on the stock, down previously from $28.00.
Low
Report
Lumos Pharma, Inc. (NASDAQ: LUMO) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.25 price target on the stock, down previously from $28.00.
10/24
07:49 am
lumo
DPV set to acquire Lumos Pharma for $38m [Yahoo! Finance]
Low
Report
DPV set to acquire Lumos Pharma for $38m [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/14
09:05 am
lumo
Form SC 14D9 LUMOS PHARMA, INC. Filed by: LUMOS PHARMA, INC.
Low
Report
Form SC 14D9 LUMOS PHARMA, INC. Filed by: LUMOS PHARMA, INC.
11/14
08:23 am
lumo
Form SC TO-T LUMOS PHARMA, INC. Filed by: Double Point Ventures LLC
Low
Report
Form SC TO-T LUMOS PHARMA, INC. Filed by: Double Point Ventures LLC
11/12
06:27 pm
lumo
Form SC 13G LUMOS PHARMA, INC. Filed by: Private Advisor Group, LLC
Low
Report
Form SC 13G LUMOS PHARMA, INC. Filed by: Private Advisor Group, LLC
11/7
03:12 pm
lumo
Form 10-Q LUMOS PHARMA, INC. For: Sep 30
Low
Report
Form 10-Q LUMOS PHARMA, INC. For: Sep 30
10/25
10:44 am
lumo
Form SCHEDULE 13G/A LUMOS PHARMA, INC. Filed by: WELLS FARGO & COMPANY/MN
Low
Report
Form SCHEDULE 13G/A LUMOS PHARMA, INC. Filed by: WELLS FARGO & COMPANY/MN
10/23
08:24 am
lumo
Form SC14D9C LUMOS PHARMA, INC. Filed by: LUMOS PHARMA, INC.
Medium
Report
Form SC14D9C LUMOS PHARMA, INC. Filed by: LUMOS PHARMA, INC.
10/23
08:10 am
lumo
Form 8-K LUMOS PHARMA, INC. For: Oct 22
Medium
Report
Form 8-K LUMOS PHARMA, INC. For: Oct 22
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/3
Form 4 LUMOS PHARMA, INC. For: Apr 01 Filed by: Langren Carl W.
13.2%
3/25 Form SC 13G Lumos Pharma, Inc. Filed by: Flynn James E 7.1%
4/7 Form 4 LUMOS PHARMA, INC. For: Apr 03 Filed by: McCracken Joseph S 3.5%
4/24 Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer 3.0%
3/27 Form 8-K LUMOS PHARMA, INC. For: Mar 27 1.4%
4/2 Lumos Pharma Promotes John C. McKew, PhD to Chief Operating Officer and Chief Scientific Officer 0.3%
3/25 Form SC 13G Lumos Pharma, Inc. Filed by: Flynn James E 7.1%
4/7 Form 4 LUMOS PHARMA, INC. For: Apr 03 Filed by: McCracken Joseph S 3.5%
4/24 Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer 3.0%
3/27 Form 8-K LUMOS PHARMA, INC. For: Mar 27 1.4%
4/2 Lumos Pharma Promotes John C. McKew, PhD to Chief Operating Officer and Chief Scientific Officer 0.3%
TOP News Decliners
4/1
Form SC 13D LUMOS PHARMA, INC. Filed by: New Enterprise Associates 14, L.P.
-7.4%
3/30 Form SC 13D LUMOS PHARMA, INC. Filed by: Blackstone Holdings II L.P. -4.0%
5/1 InflaRx N.V. (NASDAQ: LUMO) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock. -3.3%
4/29 Form 10-K/A LUMOS PHARMA, INC. For: Dec 31 -2.0%
4/16 InflaRx N.V. (NASDAQ: LUMO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. -1.7%
3/30 Form SC 13D LUMOS PHARMA, INC. Filed by: Blackstone Holdings II L.P. -4.0%
5/1 InflaRx N.V. (NASDAQ: LUMO) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock. -3.3%
4/29 Form 10-K/A LUMOS PHARMA, INC. For: Dec 31 -2.0%
4/16 InflaRx N.V. (NASDAQ: LUMO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. -1.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: